abs373.txt	introduction		bavituximab	is	an	immunomodulatory	chimeric	monoclonal	antibodythat	inhibits	phosphatidylserine	signaling	which	promotes	innate	and	adaptiveimmune	responses	in	this	phase	ib	trial	we	evaluated	the	safety	tolerability	preliminary	antitumor	activity	of	pemetrexed	carboplatin	inadvanced	non-small-cell	lung	cancer	(nsclc)	patients	methods	with	advanced	nonsquamous	nsclc	performancestatus	0	or	1	were	treated	500	mg/m2	area	underthe	curve	6	once	every	3	weeks	for	up	to	cycles	concurrent	bavituximab(0	mg/kg)	intravenously	weekly	using	a	standard	3+3	design	at	themaximum	identified	dose	additional	enrolled	furthercharacterize	profile	primary	objective	was	characterize	thesafety	determine	dose-limiting	toxicities	(dlts)	establish	therecommended	ii	combination	andcarboplatin	incurable	stage	iv	results	between	march	29	2011	december	30	2013	26	three	each	into	escalation	cohorts	therapy	well	tolerated	no	dlts	toxicitieswere	consistent	those	expected	from	pemetrexed/carboplatin	overall	responsewas	28%	median	progression-free	survival	4	8	months	and12	2	respectively	conclusion	welltolerated	however	efficacy	signal	similar	topemetrexed/carboplatin	alone	further	studies	should	focus	on	waysto	enhance	its	role
